NCT06420427Recruiting
Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery
Dynamic Monitoring of Circulating Tumor DNA (ctDNA) and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery/Treatment
Source: ClinicalTrials.gov · Last updated 20 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Assess the sensitivity, specificity, positive predictive value, and negative predictive value of dynamic monitoring of circulating tumor DNA (ctDNA) combined with circulating HPV DNA (cfHPV DNA) for early prediction of recurrence in cervical cancer post-surgery or post-treatment, and compare its advantages and disadvantages with existing diagnostic methods.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 14 May 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Diseases
- Cervical cancer
- NCT number
- NCT06420427
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Jan 2024 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with severe mental illness.
Other
- Patients who are participating in other clinical trials.
- Pregnant or breastfeeding women.
- Patients who voluntarily withdraw.
- Patients unable to complete the study protocol.
Who the study is looking for
- Patients with newly diagnosed HPV-positive cervical malignancy at stages I-IV who have not undergone surgery, radiation therapy, or chemotherapy.
- Patients must be older than 18 years of age.
- Cervical cancer patients who are eligible for surgery and/or chemoradiotherapy.
- Estimated life expectancy of more than three months.
- Understands the study protocol and voluntarily participates in the research by signing the informed consent form.
- Able to provide specimens and corresponding clinical information at each time point.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Third Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.